ArsenalBio cuts 99 jobs as it pivots to in vivo CAR-T development

ArsenalBio is cutting 99 jobs as it restructures the company around a strategic shift towards in vivo CAR-T development.

The reduction represents the majority of ArsenalBio's workforce and concentrates resources on a smaller core team focused on its new in vivo cell-therapy strategy.

The restructuring marks a significant change from the company's previous development model and reflects growing industry interest in CAR-T therapies that can potentially be generated directly inside patients.

Field	Content
Alert Type	Industry Update
Company	ArsenalBio
Update Type	Restructuring and R&D strategy shift
Jobs Affected	99 employees
Strategic Focus	In vivo CAR-T development
Therapy Area	Oncology; cell therapy
Technology or Modality	CAR-T cell therapy
Geography	United States
What Happened	ArsenalBio is eliminating 99 positions as part of a restructuring that shifts the company's development focus towards in vivo CAR-T therapies.
Why It Matters	The workforce reduction and strategic pivot represent a material change in ArsenalBio's R&D model and technology priorities.
Strategic Rationale	A smaller core team will focus resources on development of the company's in vivo CAR-T strategy.
Potential Impact	The restructuring could substantially alter ArsenalBio's pipeline, workforce requirements and future financing needs.
Key Takeaway	ArsenalBio is cutting most of its workforce and repositioning the company around in vivo CAR-T development.
What to Watch	Details of the in vivo CAR-T pipeline and the future of ArsenalBio's existing programmes.
Primary Source	BioSpace
Relevant Date	1 September 2026

---

Discover how nuaxia can support your next medical education initiative:

• Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector

• Contact us on: support@nuaxia.com